Provenge Injection
Product Images NDC 30237-8900

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Provenge (NDC 30237-8900). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dendreon Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Pro02 0012 01)

A survival curve chart comparing percent survival over time (months) from randomization between PROVENGE (sipuleucel-T) patients (N=341, red solid line) and placebo patients (N=171, blue dashed line). The y-axis shows percent survival from 0% to 100%, and the x-axis shows time from 0 to 72 months.*

FDA Label Image

Package Label 2 (Pro02 0012 04)

The label is for sipuleucel-T injection, 250 mL, with storage instructions to refrigerate at 2-8°C and a warning not to freeze. It includes an expiration date of 01-JUL-2008 and a time of 13:01 PST. Patient information fields include the last name Smith, first name John W., and date of birth 16-JUN-1951. The label also states the product is not evaluated for infectious substances and includes a lot number and QR code.*

FDA Label Image

Principal Display Panel – Carton Label (Pro02 0015 02)

Label for PROVENGE injection containing sipuleucel-T, a cellular therapy for intravenous use. It specifies a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF suspended in Lactated Ringer's Injection, USP. Manufactured by Dendreon Pharmaceuticals LLC, Seal Beach, CA. The label includes a U.S. license number and guidance to see the package insert for full prescribing information and administration instructions.*

FDA Label Image

Principal Display Panel – Bag Label (Pro02 0015 03)

Label for PROVENGE sipuleucel-T injection, a cellular therapy by Dendreon Pharmaceuticals LLC. The label specifies the product contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF in Lactated Ringer's Injection, USP. It is intended for autologous use only and includes contact information for the manufacturer.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.